A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17)
Tepotinib demonstrated consistent antitumor activity in patients with METex14, and promising antitumor activity in various cancers with MET amplification. Detection of MET dysregulation by plasma NGS may predict the response to tepotinib.
Authors
- Eun Joo Kang (ORCID: https://orcid.org/0000-0003-0702-3400)
- Kang Hyun Park (ORCID: https://orcid.org/0000-0001-9946-0522)
- Yoon Ji Choi (ORCID: https://orcid.org/0000-0002-1831-0555)
- Yu Jung Kim (ORCID: https://orcid.org/0000-0002-5037-0523)
- Woo Kyun Bae (ORCID: https://orcid.org/0000-0003-0267-1943)
- S.I. Lee
- KK Lee (ORCID: https://orcid.org/0000-0002-6520-304X)
- So Yeon Oh (ORCID: https://orcid.org/0000-0002-2562-9257)
- Hee Kyung Ahn (ORCID: https://orcid.org/0000-0001-7786-7233)
- Yaewon Yang (ORCID: https://orcid.org/0000-0002-1773-134X)
- I. Kim
- Han Suk Ryu (ORCID: https://orcid.org/0000-0003-2508-9796)
- Sang-Ho Lee (ORCID: https://orcid.org/0000-0001-5943-7715)
- Yong Jae Lee (ORCID: https://orcid.org/0000-0003-0297-3116)
- Tae Min Kim (ORCID: https://orcid.org/0000-0001-6145-4426)
- Seungtaek Lim (ORCID: https://orcid.org/0000-0001-7258-2263)
- M-J Ahn
- H-C Jeung
Institutions
- Chungbuk National University (KR)
- Yonsei University (KR)
- Korea University Medical Center (KR)
- Samsung Medical Center (KR)
- New Generation University College (ET)
- Seoul National University Hospital (KR)
- Seoul National University Bundang Hospital (KR)
- Gachon University Gil Medical Center (KR)
- National Cancer Center (US)
- Inje University Haeundae Paik Hospital (KR)
- National University College (PR)
- Chungnam National University Hospital (KR)
- Gangnam Severance Hospital (KR)
- Chonnam National University Hwasun Hospital (KR)
- Pusan National University Yangsan Hospital (KR)
- Chungbuk National University Hospital (KR)
- Korea University (JP)
- Sungkyunkwan University (KR)
- Dankook University (KR)
Publication Details
- Journal
- ESMO Open
- Published
- 2024-08-29
- DOI
- https://doi.org/10.1016/j.esmoop.2024.103668
- Citations
- 8
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 3.35
Funders
- Amgen
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Merck
- Merck KGaA
- Celltrion
- Yuhan
- Daiichi-Sankyo
- Ministry of Health and Welfare
- National Cancer Center
- Korea Health Industry Development Institute